Editas Medicine earnings missed by $0.23, revenue topped estimates

Investing.com - Editas Medicine (NASDAQ: EDIT) reported second quarter EPS of $-0.63, $0.23 worse than the analyst estimate of $-0.40. Revenue for the quarter came in at $3.58M versus the consensus estimate of $2.15M.

Editas Medicine’s stock price closed at $2.29. It is up 51.66% in the last 3 months and down -42.61% in the last 12 months.

Editas Medicine saw 2 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Editas Medicine’s stock price’s past reactions to earnings here.

According to InvestingPro, Editas Medicine’s Financial Health score is "weak performance".

Check out Editas Medicine’s recent earnings performance, and Editas Medicine’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar